Dolby Laboratories, Inc. logo DLB - Dolby Laboratories, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 8
HOLD 6
SELL 3
STRONG
SELL
0
| PRICE TARGET: $90.33 DETAILS
HIGH: $112.00
LOW: $74.00
MEDIAN: $85.00
CONSENSUS: $90.33
UPSIDE: 46.88%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 65% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Mild
Trading 9.2% above fair value
Current Price $61.50
Bear Case $47.16 23.3% downside ($47.16 - $61.50) / $61.50 = -23.3% $2.62 × 18x P/E
Fair Value $56.33 8.4% downside ($56.33 - $61.50) / $61.50 = -8.4% $2.62 × 22x P/E
Bull Case $65.50 6.5% upside ($65.50 - $61.50) / $61.50 = 6.5% $2.62 × 25x P/E

Adjust Assumptions

21.5x
2.62$

Key Value Driver

Normalized P/E multiple (22x base case)

Implied Market Multiple 23.5x

Plain-Language Summary

Applying a 22x P/E to adjusted EPS of $2.62, the base-case value is $56.33 per share. DDM cross-check: $356.39.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (17 analysts) $90.33
Analyst Range $74.00 – $112.00
Divergence from AlphaVal 38%

Warnings

Dividend-based valuation: $356.39 (above our primary estimate by 533%). Large gaps may signal the dividend doesn't reflect full earning power.
Wall Street's average price target is $90.33 (from 17 analysts). Our estimate is 38% below the consensus -- consider that gap carefully.

Key Risks

  • Growth DCF inappropriate — terminal value assumptions dominate
  • EV/EBITDA misleading for regulated businesses where capex is mandated
  • Regulatory risk is a fat tail not visible in normal multiples